Reduction of HIV-1 load in semen during follow-up study of RV144 vaccine trial boosts interest for novel correlates of immune protection in genital mucosa.

摘要

The design and production of effective vaccines against human immunodeficiency virus type 1 (HIV-1) are persisting major challenges for the HIV-1 scientific community. It also remains unclear which immune correlates should be considered as part of a successful HIV-1 vaccine and in which tissues these correlates should be measured. The discussion, which has been ongoing for the 30 years since HIV was isolated, is whether a potentially successful HIV-1 vaccine should lead to sterilizing immunity against the virus or whether a vaccine would be considered successful if the clinical syndromes linked to the infection were milder or delayed.